Manchester Royal Eye Hospital is an ophthalmic hospital in Oxford Road, Manchester, England, managed by the Manchester University NHS Foundation Trust. It is on the same site as Manchester Royal Infirmary and St Mary's Hospital for Women and Children.

During the past decade, Manchester Royal Eye Hospital conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 7 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 6 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Manchester Royal Eye Hospital" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Manchester University NHS Foundation Trust" with 3 trials sponsored, "Oraya Therapeutics, Inc." with 3 trials sponsored, "Belfast Health and Social Care Trust" with 2 trials sponsored and "Gyroscope Therapeutics Limited" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Manchester Royal Eye Hospital" #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "National Institute for Health Research, United Kingdom" with 2 trials as a collaborator, "Novartis Pharmaceuticals" with 2 trials as a collaborator, "University of Manchester" with 2 trials as a collaborator and "Bangor University" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Manchester Royal Eye Hospital" are "Macular Degeneration" (6 trials), "Diabetic Macular Edema" (4 trials), "Eye Diseases" (3 trials), "AMD" (2 trials) and "Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Manchester Royal Eye Hospital" in a lesser frequency.

Most popular intervention types in "Manchester Royal Eye Hospital" are "Drug" (10 trials), "Device" (9 trials), "Other" (4 trials), "Procedure" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Faricimab" (3 trials), "IRay" (3 trials), "Sham Procedure" (3 trials), "0.5 mg ranibizumab" (1 trials) and "Aflibercept" (1 trials). Other intervention names were less common.

The vast majority of trials in "Manchester Royal Eye Hospital" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Manchester Royal Eye Hospital". undefined are not yet recruiting, 2 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Manchester Royal Eye Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Manchester Royal Eye Hospital, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 8 trials that are defined as “Not Applicable".

Manchester Royal Eye Hospital has several departments that took part in Clinical trials: "Royal Manchester Children's Hospital" - 150 trials